Ipsen Acquires Albireo Pharma

Ipsen Acquires Epizyme

August 12, 2022

Biotechnology

Ipsen has completed the acquisition of Epizyme, Inc., acquiring all outstanding shares for $1.45 per share plus a $1.00 contingent value right and bringing Epizyme's approved oncology drug Tazverik and preclinical/clinical pipeline into Ipsen. The deal adds epigenetics-focused assets including the approved EZH2 inhibitor tazemetostat and the SETD2 inhibitor candidate EZM0414 to Ipsen's oncology portfolio and integrates Epizyme employees into Ipsen's organization.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Mirum Pharmaceuticals Acquires Bluejay Therapeutics

January 26, 2026

Pharmaceuticals

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.

Alkermes plc Acquires Avadel Pharmaceuticals plc

February 12, 2026

Pharmaceuticals

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.